DE69404460T2 - Zell-test für alzheimersche krankheit - Google Patents

Zell-test für alzheimersche krankheit

Info

Publication number
DE69404460T2
DE69404460T2 DE69404460T DE69404460T DE69404460T2 DE 69404460 T2 DE69404460 T2 DE 69404460T2 DE 69404460 T DE69404460 T DE 69404460T DE 69404460 T DE69404460 T DE 69404460T DE 69404460 T2 DE69404460 T2 DE 69404460T2
Authority
DE
Germany
Prior art keywords
alzheimer
disease
cell test
cells
intracellular calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69404460T
Other languages
English (en)
Other versions
DE69404460D1 (de
Inventor
Daniel Alkon
Rene Etcheberrigaray
Ito Etsuro
Gary Gibson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
Original Assignee
US Department of Health and Human Services
Cornell Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Cornell Research Foundation Inc filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE69404460D1 publication Critical patent/DE69404460D1/de
Publication of DE69404460T2 publication Critical patent/DE69404460T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
DE69404460T 1993-05-03 1994-05-02 Zell-test für alzheimersche krankheit Expired - Fee Related DE69404460T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/056,456 US5580748A (en) 1993-05-03 1993-05-03 Diagnostic tests for alzheimers disease
PCT/US1994/004754 WO1994025872A1 (en) 1993-05-03 1994-05-02 Cell test for alzheimer's disease

Publications (2)

Publication Number Publication Date
DE69404460D1 DE69404460D1 (de) 1997-09-04
DE69404460T2 true DE69404460T2 (de) 1998-02-26

Family

ID=22004526

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69404460T Expired - Fee Related DE69404460T2 (de) 1993-05-03 1994-05-02 Zell-test für alzheimersche krankheit

Country Status (12)

Country Link
US (1) US5580748A (de)
EP (1) EP0697111B1 (de)
JP (1) JPH09500202A (de)
AT (1) ATE155888T1 (de)
AU (1) AU689776B2 (de)
CA (1) CA2162048A1 (de)
DE (1) DE69404460T2 (de)
DK (1) DK0697111T3 (de)
ES (1) ES2108455T3 (de)
GR (1) GR3025126T3 (de)
HK (1) HK1001500A1 (de)
WO (1) WO1994025872A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300085B1 (en) 1993-05-03 2001-10-09 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic method for Alzheimer's disease
US5976816A (en) * 1993-05-03 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Cell tests for alzheimer's disease
US6107050A (en) * 1993-05-03 2000-08-22 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic test for alzheimers disease
US6573063B2 (en) * 1995-10-04 2003-06-03 Cytoscan Sciences, Llc Methods and systems for assessing biological materials using optical and spectroscopic detection techniques
US5902732A (en) * 1995-10-04 1999-05-11 Cytoscan Sciences Llc Drug screening process measuring changes in cell volume
US6183975B1 (en) * 1997-02-24 2001-02-06 J. Jay Gargus Method of detection of congenital disease
CA2308371A1 (en) * 1997-11-10 1999-05-20 David G. Grahame-Smith Method for diagnosing alzheimer's disease
US6087118A (en) * 1999-03-04 2000-07-11 Bristol-Myers Squibb Company Method for diagnosing alzheimer's disease
JP2003503083A (ja) * 1999-07-01 2003-01-28 サイオス，インコーポレーテッド アミロイド関連疾患の予防及び治療
WO2001077686A2 (en) * 2000-04-05 2001-10-18 Neurologic, Inc. Cellular calcium responce for diagnosis of alzheimer's disease
US6495335B2 (en) 2000-12-07 2002-12-17 Mario Chojkier Compositions and methods for diagnosing alzheimer's disease
GB0107231D0 (en) 2001-03-22 2001-05-16 Imp College Innovations Ltd Patch clamp
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
TW201206425A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
KR20130122630A (ko) 2005-07-29 2013-11-07 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 단독의 또는 ｐｋｃ 억제제와 배합된 ｐｋｃ 활성화제의 장기 기억 향상을 위한 용도
CA2626852A1 (en) * 2005-11-03 2007-05-18 Redpoint Bio Corporation High throughput screening assay for the trpm5 ion channel
JP2009544753A (ja) 2006-07-28 2009-12-17 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 細胞成長、シナプスリモデリング及び長期記憶の固定を刺激する方法
CA2674773A1 (en) * 2007-02-09 2008-08-21 Blanchette Rockefeller Neurosciences Institute Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
CL2007002908A1 (es) * 2007-10-09 2008-05-30 Univ Concepcion Procedimiento electroquimico in vitro para evaluar capacidad neurotoxica de estructuras, principios activos y/o compuestos de interes en celulas vivas y que comprende medir y cuantificar los parametros electricos en membranas expuestas a dichos agreg
BR112012007561A2 (pt) * 2009-10-02 2017-06-06 Blanchette Rockefeller Neurosciences Inst padrões de desenvolvimento de fibroblasto para diagnóstico de doença de alzheimer
WO2014183023A1 (en) 2013-05-09 2014-11-13 Trustees Of Boston University Using plexin-a4 as a biomarker and therapeutic target for alzheimer's disease
US20160333063A1 (en) 2013-12-13 2016-11-17 The General Hospital Corporation Soluble high molecular weight (hmw) tau species and applications thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925664A (en) * 1986-10-20 1990-05-15 University Of Utah Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
WO1989009600A1 (en) * 1988-04-08 1989-10-19 Massachusetts Institute Of Technology Method and composition for treating neurological disorders

Also Published As

Publication number Publication date
ES2108455T3 (es) 1997-12-16
AU6778494A (en) 1994-11-21
DK0697111T3 (da) 1998-03-02
GR3025126T3 (en) 1998-02-27
CA2162048A1 (en) 1994-11-10
AU689776B2 (en) 1998-04-09
DE69404460D1 (de) 1997-09-04
US5580748A (en) 1996-12-03
JPH09500202A (ja) 1997-01-07
EP0697111B1 (de) 1997-07-23
WO1994025872A1 (en) 1994-11-10
EP0697111A1 (de) 1996-02-21
ATE155888T1 (de) 1997-08-15
HK1001500A1 (en) 1998-06-19

Similar Documents

Publication Publication Date Title
DE69404460D1 (de) Zell-test für alzheimersche krankheit
DE69529992D1 (de) Cell test und diagnostischer kit für alzheimer-erkrankung
WO1999058981A3 (en) Diagnostic tests for alzheimer's disease
DE69312513D1 (de) MENSCHLICHE CYCLOOXYGENASE-2cDNA UND BESTIMMUNG VON MENSCHLICHE CYCLOOXYGENASE-2-INHIBIERUNG
WO2000066762A3 (en) Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus
ES2151880T3 (es) Antagonistas de proteina de coagulacion de la sangre y sus utilizaciones.
ATE255902T1 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv- verwandten krankheiten
AR038428A2 (es) Compuestos fluorados de marcfortina
ES2115679T3 (es) Preparacion de reactivos de tiempo de protrombina a partir de factor de tejido humano recombinante y de fosfolipidos sinteticos y naturales purificados.
DE69530933D1 (de) Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis
ATE250625T1 (de) IM WESENTLICHEN REINES ZONULIN ALS PHYSIOLOGISCHER MODULATOR VON ßTIGHT JUNCTIONSß BEI SÄUGERN
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
Seller et al. Magnesium metabolism in hypertension
Tuttle et al. Phenytoin action on the excitable membrane of mouse neuroblastoma
ES8707565A1 (es) Un procedimiento para producir un anticuerpo monoclonal
ATE178074T1 (de) Proinsulin-peptid-verbindungen für den nachweis und die behandlung von typ-i-diabetes
BR9908443A (pt) Linhagens de células de medula espinhal humana e métodos para uso das mesmas
DK0821593T3 (da) Konjugat af et aktivt middel, et protein og eventuelt et for kroppen ikke som fremmed anset nativt protein
ATE412435T1 (de) Verwendung eines färbemittels zur anfärbung von der augenlinsenkapsel oder von an der netzhaut des auges entstandenen membranen
BG102222A (en) The use of derivatives of the sulphaminic acid, acylsulphanomides or sulphamoylcarbamates for the preparation of a medicament for reducing lipoprotein levels
Petitti et al. Physiologic measures in men with and without vasectomies
ATE222762T1 (de) 4-hydroxycoumarin-3-carboxamide für die behandlung von nicht-insulin-abhängigen diabetes mellitus
AU5336796A (en) Method for detecting allergy
WO1996031621A3 (en) Method for determining the responsiveness of individuals to 5-ht2 receptor modulating agents
増山元三郎 et al. Quasi-constancy of human biochemical individual variability

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CORNELL RESEARCH FOUNDATION, INC., ITHACA, N.Y., U

8339 Ceased/non-payment of the annual fee